A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110

Summary

The purpose of this first-in human (FIH) study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of KRRO-110 in both healthy adult participants and in clinically stable patients with Alpha-1 antitrypsin deficiency (AATD).

Timeline

Start

2025-01-13

Primary completion

2025-10-31

Completion

2025-12-15

Outcome

Outcome not reported

Stopped (Business): “The study was terminated for business decision reasons.”

Drugs

Indications